The [[Malignant Ascites Treatment Market( was valued at USD 799.2 million in 2024 and is projected to reach USD 1.5 billion by 2035, expanding at a CAGR of 5.9% during 2025–2035. Market growth is being supported by the increasing prevalence of cancer-related ascites, advancements in treatment technologies, rising healthcare expenditure, and greater awareness of available treatment options. Paracentesis remains an important treatment approach, while intraperitoneal chemotherapy, diuretics, and surgical interventions are also used in the management of ascites. https://www.wiseguyreports.com/reports/malignant-ascites-treatment-market)
Technological developments and growing interest in personalized treatment approaches are contributing to the evolution of the market. Minimally invasive procedures, targeted therapies, immunotherapies, and improved drug-delivery techniques are creating opportunities for new treatment solutions. North America is projected to maintain a leading position, while Asia Pacific is expected to experience substantial growth as healthcare access and cancer-care infrastructure continue to improve.